New to the Huntington's Disease Lighthouse?
 Welcome to the HDlighthouse!
 Getting started.
 
Home \ Research \ Drugs and Supplements \ Updates
Creatine Supplementation Lowers Brain Glutamate Levels in HD patients

HD Lighthouse Contributing Editor's Comment: Short term trials of creatine have not yielded positive results despite good results in mouse models. This new study of brain metabolite levels in HD patients shows that creatine supplementation improves glutamate metabolism, known to be impaired with HD. Longer term clinical trials of creatine are warranted.
--Marsha L. Miller, Ph.D.
Posted to the HDL: 29 Jan 2005



Creatine supplementation lowers brain glutamate levels in Huntington's disease

There is evidence from in vitro and animal experiments that oral creatine (Cr) supplementation might prevent or slow down neurodegeneration in Huntington's disease (HD). However, this neuroprotective effect could not be replicated in clinical trials, possibly owing to treatment periods being too short to impact on clinical endpoints. We used proton magnetic resonance spectroscopy ((1)H-MRS) as a surrogate marker to evaluate the effect of Cr supplementation on brain metabolite levels in HD.Twenty patients (age 46+/-7.3 years, mean duration of symptoms 4.0+/-2.1 years, number of CAG repeats 44.5+/-2.7) were included. The primary endpoint was metabolic alteration as measured by (1)H-MRS in the parieto-occipital cortex before (t1) and after 8-10 weeks (t2) of Cr administration. Secondary measures comprised the motor section of the Unified Huntington's Disease Rating Scale and the Mini Mental State Examination. (1)H-MRS showed a 15.6% decrease of unresolved glutamate (Glu)+glutamine (Gln; Glu+Gln=Glx; p<0.001) and a 7.8% decrease of Glu (p<0.027) after Cr treatment. N-acetylaspartate trended to fall (p=0.073) whereas total Cr, choline-containing compounds, glucose, and lactate remained unchanged. There was no effect on clinical rating scales.This cortical Glx and Glu decrease may be explained by Cr enhancing the energy-dependent conversion of Glu to Gln via the Glu-Gln cycle, a pathway known to be impaired in HD. Since Glu-mediated excitotoxicity is presumably pivotal in HD pathogenesis, these results indicate a therapeutic potential of Cr in HD. Thus, longterm clinical trials are warranted.

Tracked on the Lighthouse:
creatine

# # #

Source: J Neurol. 2005 Jan;252(1):36-41

print this
printer friendly
version

 

Read the HDAC/HDLighthouse Forum. Post your comments
   
Related Topics
Research focusing on the formation of aggregates caused by HD
 
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
 
Research related HD and it's general affect on the brain
 
Learn more about the clinical trial process, trials that have been conducted and those that are underway.
 
Research focusing on gene therapy.
 
Research focusing on gene transcription.
 
General research related to HD
 
Research studying the genetics of Huntington's Disease
 
Research studying the Immune System and it's effect on the progression of HD
 
Research studying the brain tissue and research related to stem cells
 
Recent Updates
25 Jul 2010
Reduced Creatine Kinase
Reduced creatine kinase is a promising biomarker.
 
14 Apr 2010
CoQ10 and Minocycline not helpful in Mouse Model
Neither CoQ10 nor minocycline were helpful in the R6/2 mouse and high doses of minocycline resulted in decreased survival time.
 
5 Dec 2009
Cogane
A new BDNF inducer enters the pipeline.
 
24 Apr 2009
An ampakine upregulates BDNF
An ampakine, a modulator of glutamate receptors, reduced memory and learning problems in HD mice.
 
8 Apr 2009
Amarin files new drug application for AMR 101 in Europe
Ethyl-EPA remains in the drug development pipeline.
 
3 Feb 2009
The ACR-16 trial is enrolling participants
An interview with lead investigator Dr. Karl Kieburtz.
 
31 Jan 2009
Surprising Finding Points to Possible Treatment for Huntington Disease
Drugs that increase the activity of PPAR-delta are added to the pipeline of potential treatments.
 
1 Jan 2009
Long term tetrabenazine use
In an Italian study, TBZ improved chorea for most patients; over time the magnitude of the benefit declined somewhat.
 
15 Dec 2008
Ethyl-EPA research report published
Ethyl-EPA is still in the research pipeline.
 
13 Oct 2008
Ethyl-EPA reduces cerebral atrophy in HD patients
Treatment with ethyl-EPA is associated with significant reduction in brain atrophy, particularly in the caudate and thalamus.
 

All Updates for Drugs and Supplements
Disclaimer & Privacy Policy | Welcome | Site Feedback Marsha@HDLighthouse.org